首都医科大学学报 ›› 2009, Vol. 30 ›› Issue (5): 626-630.doi: 10.3969/j.issn.1006-7795.2009.05.012

• 艾滋病基础研究及治疗 • 上一篇    下一篇

20例HIV/AIDS患者耐药结果分析

魏飞力1, 吴昊2, 张彤2, 李庆1, 刘志英1, 王蕊1, 焦艳梅1, 陈德喜1   

  1. 1. 首都医科大学附属北京佑安医院性病艾滋病实验室;2. 首都医科大学附属北京佑安医院感染科
  • 收稿日期:2009-07-16 修回日期:1900-01-01 出版日期:2009-10-21 发布日期:2009-10-21
  • 通讯作者: 陈德喜

Analysis of Drug Resistance Results in 20 Cases of HIV/AIDS Patients

WEI Fei-li1, WU Hao2, ZHANG Tong2, LI Qing1, LIU Zhi-ying1, WANG Rui1, JIAO Yan-mei1, CHEN De-xi1   

  1. 1. HIV/AIDS & STD Laboratory, Beijing Youan Hospital, Capital Medical University;2. Department of Infectious Diseases, Beijing Youan Hospital, Capital Medical University
  • Received:2009-07-16 Revised:1900-01-01 Online:2009-10-21 Published:2009-10-21

摘要: 目的 对高效抗逆转录病毒治疗(highly active antiretroviral therapy,HAART)失败的HIV/AIDS患者,进行回顾性基因型耐药检测,了解HAART过程中HIV-1耐药位点的产生,分析基因型耐药检测在HAART过程中的必要性及指导意义。方法 采用Versant HIV-1 RNA 3.0检测病毒载量;采用TriTEST CD4 FITC/CD8 PE/CD3 PerCP Reagent检测CD4+T淋巴细胞计数;采用Trugene HIV-1 Genotyping Kit和OpenGene DNA系统进行基因型耐药检测;用Blast等分子生物学软件进行HIV-1亚型分析。结果 20例患者中,17例保存有治疗前的血浆标本,其中1例在治疗前即存在非核苷类逆转录酶抑制剂(non-nucleoside reverse transcriptase inhibitors,NNRTIs)耐药相关突变。20例患者均进行了治疗后耐药检测,其中3例未检出耐药相关突变。其他17例检出耐药相关突变,其中13例出现NNRTIs耐药相关突变;突变位点主要为K103N、Y188L、Y181C、V106M和G190A;11例显示有核苷类逆转录酶抑制剂(nucleoside/nucleotide reverse transcriptase inhibitors,NRTIs)耐药相关突变,突变位点主要为M184V、T/215Y/F、D67N、K70R以及K219E/Q;3例出现蛋白酶抑制剂(protease inhibitors, PIs)耐药相关突变,其中主突变为M46I/L、V82F/A,而次级突变中以M36I、L63P出现的频率最高。20例患者中B亚型9例(45%, 9/20),CRF01_AE重组亚型 5例(25%,5/20),CRF07_BC重组亚型5例(25%, 5/20),CRF06_CPX1重组亚型1例(5%, 1/20)。结论 对治疗失败的患者进行基因型耐药检测可以帮助医生判断HAART失败的原因,并指导治疗方案的优化;亚型分析显示HIV-1病毒亚型的流行与感染途径之间存在明显的联系。

关键词: HIV-1, 高效抗逆转录病毒治疗(HAART), 基因型耐药, 突变

Abstract: Objective To analyze drug resistance status in 20 HIV/AIDS patients who had received highly active antiretroviral therapy(HAART) with treatment failure and to evaluate the significance of drug resistance test. Methods Plasma viral load, CD4+ T lymphocyte counts were determined by Versant HIV-1 RNA 3.0 and TriTEST CD4 FITC/CD8 PE/CD3 PerCP Reagent, respectively. Using the Trugene HIV-1 Genotyping kit and OpenGene DNA Sequencing System, we sequenced HIV-1 target genes and analyzed drug-related mutations. We used molecular biology software(such as Blast) to identify HIV-1 subtypes. Results Of the 20 patients, 17 had pre-treatment plasma samples, and 1 case showed an non-nucleoside reverse transcriptase inhibitors(NNRTIs)-related resistance mutation before HAART. When antiviral treatment initiated, 3/20 cases with no drug resistanceǒrelated mutations were found at any time point; in 17/20 cases drug resistanceǒrelated mutation was detected. Thirteen of 17 patients showed NNRTI-related mutations, mostly in K103N, Y188L, Y181C, V106M and G190A. Eleven of 17 patients showed Nucleoside/Nucleotide Reverse Transcriptase Inhibitors(NRTIs)-related mutations, mostly in M184V, T/215Y/F, D67N, K70R and K219E/Q. Three of 17 patients were showed Protease Inhibitors(PIs)-related mutations, with primary mutation site at M46I/L and V82F/A. In secondary mutation of PI, M36I and L63P were the most common sites. Of the 20 patients, had type B infection, had 5(25%, 5/20) CRF01_AE recombinants another, had 5(25%, 5/20) CRF07_BC recombinants, had CRF06_CPX1 recombinants is 1(5%, 1/20). Conclusion For patients with treatment failure and drug-resistance, mutation detection can help clinicians determine the cause of treatment failure and optimize the medication combinations. Termination or change of treatment programs could significantly affect drug resistance test results, and therefore, clinicians should be fully aware of the treatment situation of patients before drug resistance test. The subtypes revealed that the HIV subtypes have an association with routes of infection.

Key words: human immunodeficiency virus(HIV-1), highly active antiretroviral therapy(HAART), genotyping resistance, mutation

中图分类号: